uniQure N.V. (QURE)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with QURE?
Powered by Yahoo ScoutuniQure (QURE) has submitted a Biologics License Application for its gene therapy targeting Huntington's disease, signaling significant progress despite concerns over its high valuation. The stock has surged nearly 7xin three years, yet analysts warn that any setbacks could impact its current pricing heavily.
- Previous Close
44.86 - Open
44.91 - Bid --
- Ask --
- Day's Range
43.90 - 45.12 - 52 Week Range
8.73 - 71.50 - Volume
-- - Avg. Volume
-- - Market Cap (intraday)
3.087B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Recent News
Statistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (5yr expected)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
--
-
Return on Assets (ttm)
--
-
Return on Equity (ttm)
--
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
--
-
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
-
Total Cash (mrq)
--
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
--
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
